是时候重新思考肺癌免疫治疗时代的铂类选择了。 - Suppr | 超能文献

Time to rethink platinum choices in the era of immunotherapy in lung cancer.

作者信息

Harris E, Taflin N F, Chitkara A, Tagliamento M, Bestvina C M, Vakkalagadda C V, Besse B, Thawani R

机构信息

Department of Medicine, University of Chicago, Chicago, USA.

Division of Oncology, Department of Internal Medicine, University of Utah, Salt Lake City, USA.

出版信息

Ann Oncol. 2025 Feb;36(2):218-220. doi: 10.1016/j.annonc.2024.10.009. Epub 2024 Oct 11.

DOI:10.1016/j.annonc.2024.10.009

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Time to rethink platinum choices in the era of immunotherapy in lung cancer.是时候重新思考肺癌免疫治疗时代的铂类选择了。

Ann Oncol. 2025 Feb;36(2):218-220. doi: 10.1016/j.annonc.2024.10.009. Epub 2024 Oct 11.

2

Immunotherapy: a new era in small-cell lung cancer.免疫疗法：小细胞肺癌的新时代。

Lancet. 2019 Nov 23;394(10212):1884-1885. doi: 10.1016/S0140-6736(19)32235-4. Epub 2019 Oct 4.

3

Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?重新审视转移性尿路上皮癌的治疗：顺铂和铂类不适用标准现状如何？

Biomedicines. 2024 Feb 26;12(3):519. doi: 10.3390/biomedicines12030519.

4

Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy.免疫治疗时代之前真实世界证据ESME队列中广泛期小细胞肺癌（SCLC）的治疗模式和临床结局

Respir Med Res. 2023 Nov;84:101012. doi: 10.1016/j.resmer.2023.101012. Epub 2023 Mar 27.

5

Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer.免疫治疗时代转移性非小细胞肺癌死因的真实世界景观转变。

Front Immunol. 2022 Nov 11;13:1058819. doi: 10.3389/fimmu.2022.1058819. eCollection 2022.

6

DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients.DNA 损伤反应和修复基因突变与晚期 NSCLC 患者基于铂类的化疗/免疫治疗的肿瘤突变负担和结局相关。

Diagn Pathol. 2023 Nov 3;18(1):119. doi: 10.1186/s13000-023-01401-0.

7

Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.奥希替尼进展后，化疗联合免疫疗法与化疗联合贝伐单抗及单纯化疗治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）的比较

Clin Lung Cancer. 2022 May;23(3):e210-e221. doi: 10.1016/j.cllc.2021.11.001. Epub 2021 Nov 11.

8

Response to platinum-based therapies in second-line after immunotherapy in advanced or metastatic non-small-cell lung cancer PD-L1 ≥50.在晚期或转移性非小细胞肺癌中，免疫治疗后二线铂类疗法对PD-L1≥50患者的疗效。

Transl Lung Cancer Res. 2024 Oct 31;13(10):2649-2659. doi: 10.21037/tlcr-24-513. Epub 2024 Oct 24.

9

Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy.铂类化疗后非小细胞肺癌中免疫检查点抑制剂的真实世界比较

J Oncol Pharm Pract. 2020 Apr;26(3):564-571. doi: 10.1177/1078155219855127. Epub 2019 Jun 25.

10

Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.一线免疫检查点抑制剂与医疗保险覆盖的晚期非小细胞肺癌患者生存的关联。

JAMA Netw Open. 2021 May 3;4(5):e2111113. doi: 10.1001/jamanetworkopen.2021.11113.

引用本文的文献

1

Artemisinin derivatives differently affect cell death of lung cancer subtypes by regulating GPX4 in patient-derived tissue cultures.青蒿素衍生物通过调节患者来源组织培养物中的谷胱甘肽过氧化物酶4（GPX4），对肺癌亚型的细胞死亡产生不同影响。

Cell Death Discov. 2025 May 28;11(1):256. doi: 10.1038/s41420-025-02537-2.